LLY240726P952500
- 19.15
- 0.000.00%
Eli Lilly and Co Newsroom
Cantor Fitzgerald Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $885
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
Express News | Eli Lilly and Novo Nordisk Shares Are Trading Lower After Competitor Viking Announced the Advancement of Its Obesity Candidate
The “up-and-coming diet drug” Viking (VKTX.US) drug enters the late stages of development, and the “Nolie” stock price fell in shock
As the Viking diet pill entered the later stages of clinical trials, Eli Lilly and Novo Nordisk stock prices declined.
Viking Sends Lilly, Novo Lower as Obesity Drug Enters Late-stage Program
Elon Musk Agrees With Former Executive Who Thinks 'Everyone' Has 'Strong' Opinions On Tesla Unlike In The Case Of Eli Lilly And LVMH
Expert Outlook: Eli Lilly and Co Through The Eyes Of 25 Analysts
Express News | Cantor Fitzgerald Reiterates Overweight on Eli Lilly and Co, Maintains $885 Price Target
Eli Lilly and Co Analyst Ratings
Wolfe Research Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,117
This Vanguard ETF Is Tanking. It's Big Tech's Fault.
Wolfe Research Adjusts Eli Lilly's Price Target to $1,117 From $909
What Lies in Store for Healthcare ETFs in Q2 Earnings?
Jim Cramer Thinks Eli Lilly (LLY) Has a 'Huge Lead' in Weight Loss Industry, Stock Is on 'Sale'
Novo Nordisk's Stock Dips In Pre-Market Despite Winning UK's Approval Of Weight Loss Drug: What's Going On
Rate Cuts Are Coming. These Are Some of the Stocks to Buy Now.
Election Watch: Will Conservatives and Liberals Move the Meter With Their Stock Picks?
Market Whales and Their Recent Bets on LLY Options
Time for Healthcare ETFs?
Eli Lilly (LLY) Advances But Underperforms Market: Key Facts